Sophiris Bio, Inc. (SPHS) financial statements (2020 and earlier)

Company profile

Business Address 1258 PROSPECT STREET
LA JOLLA, CA 92037
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 13262982348
Cash and cash equivalents 1116136415
Short-term investments 2101631933
Other undisclosed cash, cash equivalents, and short-term investments    00 
Receivables  0000 
Prepaid expense 011034
Other undisclosed current assets 0  (0)(0)0
Total current assets: 13273092652
Noncurrent Assets
Property, plant and equipment 000000
Other noncurrent assets  00000
Total noncurrent assets: 000000
TOTAL ASSETS: 13273092652
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 322165
Accounts payable 210131
Accrued liabilities 112122
Employee-related liabilities     11
Interest and dividends payable     0 
Debt 20 217
Other undisclosed current liabilities     (1)(1)
Total current liabilities: 5323611
Noncurrent Liabilities
Long-term debt and lease obligation 56 45 
Long-term debt, excluding current maturities 56 45 
Liabilities, other than long-term debt 11013001
Deferred compensation liability, classified   000 
Derivative instruments and hedges, liabilities 11013  1
Other undisclosed noncurrent liabilities      0
Total noncurrent liabilities: 61713451
Total liabilities: 11191671112
Stockholders' equity
Stockholders' equity attributable to parent, including: 281421540
Common stock 131131131114113111
Additional paid in capital 272624181714
Accumulated other comprehensive income 000000
Accumulated deficit (156)(150)(141)(130)(116) 
Other undisclosed stockholders' equity attributable to parent      (85)
Total stockholders' equity: 281421540
TOTAL LIABILITIES AND EQUITY: 13273092652

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 000005
Revenue, net    5
Net investment income 00000 
Cost of revenue
(Cost of Goods and Services Sold)
    (1)(1)(1)
Gross profit: 000(1)(1)4
Operating expenses (15)(12)(10)(13)(30)(15)
Operating loss: (15)(12)(10)(14)(31)(10)
Nonoperating income (expense) 83(1)(1)(1)(1)
Foreign currency transaction loss, before tax     (0)(0)
Other nonoperating income (expense) 0(0)(0)(0)(0)(0)
Interest and debt expense (1)(0)0(1)(1)(1)
Loss from continuing operations before equity method investments, income taxes: (7)(9)(11)(15)(32)(13)
Other undisclosed income (loss) from continuing operations before income taxes 0(0)(0)112
Loss from continuing operations before income taxes: (7)(9)(11)(14)(31)(11)
Income tax expense      (1)
Net loss available to common stockholders, diluted: (7)(9)(11)(14)(31)(11)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (7)(9)(11)(14)(31)(11)
Comprehensive loss: (7)(9)(11)(14)(31)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0(0)  00
Comprehensive loss, net of tax, attributable to parent: (7)(9)(11)(14)(31)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: